(Q47918461)

6 February 2018

reason for preferred rank

title

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b (English)

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

1 January 2024

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743232

severity of illness index

1 January 2024

main subject

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743232

1 January 2024

7

M. Filippi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743232

1 January 2024

author name string

European Study Group on Interferon Beta-1b in Secondary Progressive MS

8

1 reference

6 February 2018

M. P. Sormani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743232

1 January 2024

P. Bruzzi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743232

1 January 2024

K. Beckmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743232

1 January 2024

K. Wagner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743232

1 January 2024

D. H. Miller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743232

1 January 2024

L. Kappos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12743232

1 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

6 February 2018

13 May 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12743232

full work available at URL

1 January 2024

https://www.neurology.org/doi/pdfdirect/10.1212/01.WNL.0000063312.15758.B3

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

1 January 2024

1 reference

6 February 2018

volume

60

1 reference

6 February 2018

issue

9

1 reference

6 February 2018

page(s)

1462-1466

1 reference

6 February 2018

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

cites work

1

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis

1 January 2024

2

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials

1 January 2024

3

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

1 January 2024

4

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis.

1 January 2024

5

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Surrogate endpoints in clinical trials: definition and operational criteria

1 January 2024

6

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

1 January 2024

7

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Relapses and progression of disability in multiple sclerosis

1 January 2024

8

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS

1 January 2024

10

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

1 January 2024

11

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS.

1 January 2024

12

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 January 2024

13

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Estimating the proportion of treatment effect explained by a surrogate marker.

1 January 2024

14

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials.

1 January 2024

15

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 January 2024

16

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Surrogate markers in AIDS and cancer trials

1 January 2024

17

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Surrogate markers in AIDS: where are we? Where are we going?

1 January 2024

18

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

1 January 2024

19

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

MRI techniques to monitor MS evolution: the present and the future

1 January 2024

21

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Estimating the proportion of treatment effect explained by a surrogate marker.

1 January 2024

22

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results

1 January 2024

23

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 January 2024

24

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Criteria for the validation of surrogate endpoints in randomized experiments.

1 January 2024

26

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

The validation of surrogate endpoints in meta-analyses of randomized experiments

1 January 2024

27

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

Estimating the proportion of treatment effect explained by a surrogate marker

1 January 2024

28

1 reference

https://api.crossref.org/works/10.1212/01.WNL.0000063312.15758.B3

1 January 2024

Identifiers

1 reference

6 February 2018

1 reference

6 February 2018